News
CMMB
1.590
+2.58%
0.040
Earnings Scheduled For March 31, 2023
Benzinga · 1d ago
A Preview Of Chemomab Therapeutics's Earnings
Benzinga · 2d ago
BRIEF-Chemomab Therapeutics To Provide A Corporate Update On April 17, 2023
Reuters · 3d ago
BRIEF-Chemomab Therapeutics To Discuss Fourth Quarter Results
Reuters · 03/17 11:05
Ocean, NeoGenomics top healthcare gainers; Chemomab, American Well among losers
Seeking Alpha · 02/23 15:01
Hoth, CVRx top healthcare gainers; Quoin, Chemomab among losers
Seeking Alpha · 02/22 15:04
CoStar Group, AngloGold Ashanti, ZIPRECRUITER among premarket losers' pack
Seeking Alpha · 02/22 13:32
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 02/22 13:06
Why CVRx Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga · 02/21 19:07
Why Chemomab Therapeutics Shares Are Trading Higher Today
Benzinga · 02/21 18:10
SRNE, RETA and ZDGE among mid-day movers
Seeking Alpha · 02/21 17:52
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 02/21 17:31
FDA Gives Green Signal To Chemomab Therapeutics' Rare Disease Study
Benzinga · 02/21 16:46
Chemomab stock surges ~15% on FDA nod to start trial of CM-101 for systemic sclerosis
Seeking Alpha · 02/21 16:43
Sector Update: Health Care Stocks Edge Above Tuesday Intraday Lows
Sector Update: Health Care Stocks Edge Above Tuesday Intraday Lows
MT Newswires · 02/21 16:31
Ambrx, Meihua top healthcare gainers; Aileron, CVRx lead losers' pack
Seeking Alpha · 02/21 15:01
Sector Update: Health Care Stocks Falling with Broader Tuesday Markets
Sector Update: Health Care Stocks Falling with Broader Tuesday Markets
MT Newswires · 02/21 14:08
Chemomab Therapeutics stock soars after FDA clears IND for SSc treatment
MarketWatch · 02/21 13:25
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 02/21 13:06
Chemomab : FDA Clears IND Application For Phase 2 Trial Of CM-101 In Systemic Sclerosis; Stock Up
NASDAQ · 02/21 12:36
More
Webull provides a variety of real-time CMMB stock news. You can receive the latest news about Chemomab Therapeutics Ltd through multiple platforms. This information may help you make smarter investment decisions.
About CMMB
Chemomab Therapeutics Ltd, formerly known as Anchiano Therapeutics Ltd, is a Israel-based biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.